CETUXIMAB

Search structure
Trade Names:
Synonyms:
Status: Approved (2004)
Entry Type: Antibody
Molecule Category: UNKNOWN
ATC: L01XC06
UNII: PQX0D8J21J

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Epidermal growth factor receptor erbB1 inhibitor DailyMed
Primary Target
epidermal growth factor receptor

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neoplasms 4 D009369 ClinicalTrials
Colorectal Neoplasms 4 D015179 ClinicalTrials
Carcinoma, Squamous Cell 4 D002294 ClinicalTrials
Head and Neck Neoplasms 4 D006258 ClinicalTrials
Carcinoma, Squamous Cell 4 D002294 ClinicalTrials
Head and Neck Neoplasms 4 D006258 ClinicalTrials
Colorectal Neoplasms 4 D015179 ClinicalTrials
Colorectal Neoplasms 4 D015179 ClinicalTrials
Head and Neck Neoplasms 4 D006258 ClinicalTrials
Esophageal Neoplasms 3 D004938 ClinicalTrials
Stomach Neoplasms 3 D013274 ClinicalTrials
Esophageal Neoplasms 3 D004938 ClinicalTrials
Colonic Neoplasms 3 D003110 ClinicalTrials
Esophageal Neoplasms 3 D004938 ClinicalTrials
Colonic Neoplasms 3 D003110 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 3 D002289 ClinicalTrials
Stomach Neoplasms 3 D013274 ClinicalTrials
Rectal Neoplasms 3 D012004 ClinicalTrials
Pancreatic Neoplasms 3 D010190 ClinicalTrials
Squamous Cell Carcinoma of Head and Neck 3 D000077195 ClinicalTrials
Nasopharyngeal Neoplasms 3 D009303 ClinicalTrials
Squamous Cell Carcinoma of Head and Neck 3 D000077195 ClinicalTrials
Lung Neoplasms 3 D008175 ClinicalTrials
Esophageal Neoplasms 3 D004938 ClinicalTrials
Stomach Neoplasms 3 D013274 ClinicalTrials
Peritoneal Neoplasms 2 D010534 ClinicalTrials
Laryngeal Neoplasms 2 D007822 ClinicalTrials
Liver Neoplasms 2 D008113 ClinicalTrials
Uterine Cervical Neoplasms 2 D002583 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Ovarian Neoplasms 2 D010051 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 2 D064129 ClinicalTrials
Endometrial Neoplasms 2 D016889 ClinicalTrials
Carcinoma, Hepatocellular 2 D006528 ClinicalTrials
Adenocarcinoma 2 D000230 ClinicalTrials
Glioblastoma 2 D005909 ClinicalTrials
Sarcoma 2 D012509 ClinicalTrials
Carcinoma 2 D002277 ClinicalTrials
Prostatic Neoplasms 2 D011471 ClinicalTrials
Uterine Cervical Neoplasms 2 D002583 ClinicalTrials
Multiple Myeloma 2 D009101 ClinicalTrials
Laryngeal Neoplasms 2 D007822 ClinicalTrials
Anus Neoplasms 2 D001005 ClinicalTrials
Mouth Neoplasms 2 D009062 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Tongue Neoplasms 2 D014062 ClinicalTrials
Biliary Tract Neoplasms 2 D001661 ClinicalTrials
Cholangiocarcinoma 2 D018281 ClinicalTrials
Carcinoma, Verrucous 2 D018289 ClinicalTrials
Oropharyngeal Neoplasms 2 D009959 ClinicalTrials
Adenocarcinoma of Lung 2 D000077192 ClinicalTrials
Skin Neoplasms 2 D012878 ClinicalTrials
Neoplasm Metastasis 2 D009362 ClinicalTrials
Fallopian Tube Neoplasms 2 D005185 ClinicalTrials
Peritoneal Neoplasms 2 D010534 ClinicalTrials
Hypopharyngeal Neoplasms 2 D007012 ClinicalTrials
Neuralgia 2 D009437 ClinicalTrials
Complex Regional Pain Syndromes 2 D020918 ClinicalTrials
Urinary Bladder Neoplasms 2 D001749 ClinicalTrials
Anus Neoplasms 2 D001005 ClinicalTrials
Oropharyngeal Neoplasms 2 D009959 ClinicalTrials
Oropharyngeal Neoplasms 2 D009959 ClinicalTrials
Glioma 2 D005910 ClinicalTrials
Carcinoma, Adenoid Cystic 1 D003528 ClinicalTrials
Chordoma 1 D002817 ClinicalTrials
Brain Neoplasms 1 D001932 ClinicalTrials
Leukemia, Prolymphocytic 1 D015463 ClinicalTrials
Astrocytoma 1 D001254 ClinicalTrials

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Skin and subcutaneous tissue disorders
14.48
General disorders and administration site conditions
10.73
Gastrointestinal disorders
10.14
Respiratory, thoracic and mediastinal disorders
8.46
Investigations
6.64
Injury, poisoning and procedural complications
6.12
Vascular disorders
5.48
Metabolism and nutrition disorders
5.22
Blood and lymphatic system disorders
5.09
Immune system disorders
4.66
Nervous system disorders
4.57
Infections and infestations
4.54
Cardiac disorders
3.47
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
2.3

Cross References

Resources Reference
CAS NUMBER 205923-56-4
ChEMBL CHEMBL1201577
FDA SRS PQX0D8J21J
Guide to Pharmacology 6882
CONTENTS